PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

Q: What is the PRCT stock price target?

Take-profit $26.87 (+18.0% upside). Prior stop was $21.19.

Q: Is PRCT overvalued or undervalued?

PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -24.6). TrendMatrix value score: 7.5/10. Overall verdict: Sell.

Q: What do analysts say about PRCT?

21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $31.

SellVALUE-TRAP 3/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Medical Devices

$23.23+18.0% A.UpsideScore 4.8/10#35 of 40 Medical Devices

Stop $21.19Target $26.87(analyst − 13%)A.R:R 1.4:1

Analyst target$30.89+33.0%9 analysts

$26.87our TP

$23.23price

$30.89mean

$20

$37

Sell if holding. Engine safety override at $23.23: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 11%; Elevated put/call ratio: 9.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.

Passes 3/7 gates (no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.0 < 4.0)

Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-24.6

Mkt Cap$1.2B

EV/EBITDA-10.4

Profit Mgn-31.0%

ROE-24.9%

Rev Growth11.9%

Beta0.93

DividendNone

Rating analysts21

Quality Signals

Piotroski F6/9

Options Flow

P/C9.82bearish

IV93%elevated

Max Pain$18-24.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality3.015%0.45

Growth5.515%0.82

Momentum1.610%0.16

Sentiment6.910%0.69

Insider Activity6.310%0.63

Peer Rank2.710%0.27

Technical Setup4.55%0.23

Risk Profile3.85%0.19

Catalyst4.75%0.24

Overall (Σ contributions)4.80

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.6

Macd

0.7

Obv

1.0

Ma Position

1.0

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA, MA slope -13.5%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.5

Value Rank

3.5

Growth Rank

5.7

Unprofitable operations — net margin -31.0%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

5.0

Current Ratio

6.2

Piotroski F

6.7

Gross Margin

8.7

Cash-burning: FCF -8% of revenueNo competitive moatQuality concerns

GatesMomentum 1.6<4.5A.R:R 1.4 < 1.5@spotINSIDER 0.80%=EXTREMEDeath cross (50MA < 200MA)No SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

48 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $21.28Resistance $26.04

Price Targets

$21

$27

A.Upside+15.7%

A.R:R1.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.0 < 4.0)

! Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap)

! Momentum score 1.6/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-04-29 (nulld)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PRCT stock a buy right now?

Sell if holding. Engine safety override at $23.23: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 11%; Elevated put/call ratio: 9.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $21.19. Score 4.8/10, moderate confidence.

What is the PRCT stock price target?

Take-profit target: $26.87 (+18.0% upside). Prior stop was $21.19. Stop-loss: $21.19.

What are the risks of investing in PRCT?

Quality below floor (3.0 < 4.0); Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap).

Is PRCT overvalued or undervalued?

PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -24.6). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about PRCT?

21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $31.

What does PROCEPT BioRobotics Corporation do?PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the...

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.